KRCA-0713

• Description:

  KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib[1].

• UNSPSC:

  12352005

• Target:

  Anaplastic lymphoma kinase (ALK)

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/krca-0713.html

• Smiles:

  O=S (C1=C (NC2=NC (NC3=C (OC) C=C (C (C) (C (CC4) N) C) C4=C3) =NC=C2Cl) C=CC=C1) (C (C) C) =O

• Molecular Formula:

  C26H32ClN5O3S

• Molecular Weight:

  530.08

• References & Citations:

  [1]Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1884321-89-4